Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Multiple Myeloma 117Leukemia, Lymphocytic, Chronic, B-Cell 70Hodgkin Disease 65Neoplasms, Plasma Cell 64Lymphoma, Non-Hodgkin 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Lymphoma, Follicular 60Leukemia, Myeloid, Acute 59Lymphoma, Mantle-Cell 58Lymphoma, Large B-Cell, Diffuse 56Lymphoma, B-Cell, Marginal Zone 53Burkitt Lymphoma 52Myelodysplastic Syndromes 50Lymphoma, Large-Cell, Immunoblastic 50Myeloproliferative Disorders 47Leukemia, Myeloid, Chronic-Phase 44Leukemia 44Lymphoma 42Leukemia, Myeloid, Accelerated Phase 40Congenital Abnormalities 39Waldenstrom Macroglobulinemia 35Leukemia, Myelomonocytic, Chronic 34Lymphoma, T-Cell, Cutaneous 32Blast Crisis 31Sezary Syndrome 30Primary Myelofibrosis 30Mycosis Fungoides 30Recurrence 28Dendritic Cell Sarcoma, Interdigitating 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25

Interventions

Melphalan 2Filgrastim 2Fibroblast Growth Factor 7 2Cyclophosphamide 2Amifostine 2sargramostim 1Sirolimus 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Ifosfamide 1Etoposide 1Epoetin Alfa 1Deoxycytidine 1Cytarabine 1Carboplatin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Peripheral Blood Stem Cell Transplantation × Plasma cell × Clear all
NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡